Get started

REGN

$REGN LongThis is just my observation, but not an advice. Technical: REGN touched its two strong trendline since 2020 and 2021. REGN reached the 50% correction since 2020. REGN is oversold daily and weekly. A significant divergence is observable on daily chart. Price touched SMA 200. Fundamental: P/E: 16.9x (moderate undervalue) Since last ATH NASDAQ:REGN has come up with wide ranges of successful clinical trial outcomes. Nonetheless, prices dropped due to competitive pressures on Eylea. Last week, after significant clinical trial results of Odronextamab and Poze-Cemdi, the market moved up. However, the price slid after the BoA's PT revision. Analyst sentiments: 17 buy, 7 buy, 1 sell (BoA) The long possibility is high from now on.
NASDAQ:REGNLong
by jack_the_real_trader
EXCLUSIVE EWTX 350% BUY/HOLD techs/fundies with catalyst🔸Let's review EWTX daily price chart. Strong V-shape recovery in progress. YTD gains at 218% off the lows, which is an EXCELLENT indicator of the overall health of the stock. Trading 5% below 52 week high. 🔸Based on technicals, I envision a C*H breakout in 2025 after we hit overhead resistance we can expect a pullback in order to fill the massive liquidity gap left behind near 22 USD. currently stock is trading near 35 handle and expecting limited upside going forward into Q4 2024. Market cap is hovering near 3 Bln USD so it's not a penny stock and also market cap is not inflated. 🔸CYTK competitor stock chart on the right, similarly priced and also same line of business as EWTX. Trading at 53 USD now previously maxed out at 100 USD, current CYTK market cap is 6 Bln USD, at the peak market cap was 12 Bln USD. So potentially EWTX can do x4 from current levels in order to hit CYTK max market cap. this means x4 stock prices for EWTX from current levels, so it's 34 x 4 = 136 USD max projected stock price. 🔸My PT for EWTX in 2025 is 100 USD, based on the technicals and fundamentals. Recommended strategy bulls: wait for pullback/rejection from overhead resistance and be ready to BUY/HOLD once we do a COMPLETE gap fill of the liquidity gap near 22 USD. Target is 100 USD, 350%+ upside from entry price. Good luck traders! 🔸Below supplementary fundies info on EWTX / some info on the positive catalysts, you can dig deeper if required. 🔸Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious muscle diseases, particularly rare neuromuscular and cardiac disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company leverages its deep expertise in muscle biology to create innovative therapies aimed at unmet medical needs. 🔸Their lead product candidate, EDG-5506, is being developed to treat Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). This small molecule is designed to prevent contraction-induced muscle damage, offering potential benefits in improving muscle function for patients with ystrophinopathies. The drug is currently in Phase 2 trials, and has shown promising results in reducing muscle damage biomarkers​ ​ 🔸Another key program focuses on EDG-7500, an experimental therapy for hypertrophic cardiomyopathy (HCM). This drug is a selective sarcomere modulator designed to improve cardiac relaxation and contraction. The company initiated Phase 1 trials for EDG-7500 in 2023​. ​ 🔸Edgewise is dedicated to both advancing scientific research and engaging with patient communities, frequently collaborating with organizations such as the Muscular Dystrophy Association and the Parent Project Muscular Dystrophy 🔸The biotech company tested its drug, EDG-7500, in healthy volunteers and patients with obstructive hypertrophic cardiomyopathy. In this disease, a genetic mutation causes the heart ventricles to thicken. This limits cardiac function and exercise capacity. 🔸After a single dose, patients showed improved blood flow from the left ventricle. But sometimes drugs can do their job too well, suppressing cardiac function — a measure known as reduced left ventricular ejection fraction, or LVEF. But patients didn't show meaningful reductions in LVEF. 🎁Please hit the like button and 🎁Leave a comment to support our team! RISK DISCLAIMER: Trading Futures , Forex, CFDs and Stocks involves a risk of loss. Please consider carefully if such trading is appropriate for you. Past performance is not indicative of future results. Always limit your leverage and use tight stop loss.
NASDAQ:EWTXLong
by ProjectSyndicate
13
IS THE REGENERON PHARMACEUTICALS INC IS READY FOR A NEW ALL-TIMEIs Regeneron Pharmaceuticals ready for a new all-time high, or will it test again the previous one at $620 from October 2020 and confirm it as a strong resistance? Regeneron Pharmaceuticals is a leading-edge biotech and pharmaceutical company that focuses on cytokines and tyrosine kinase receptors at the cellular level. First, Regeneron developed an experimental antibody cocktail to treat COVID-19 called REGN-COV2. This treatment was granted emergency use authorization by the FDA and was even provided to former President Trump when he contracted the virus. They have a diverse product offering outside of COVID-19 offerings and some exciting possibilities in their pipeline. Also, they recently announced a new partnership with the British pharmaceutical company AstraZeneca to research and developed small molecule compounds targeting the GPR75 gene. This is also promising because the Regeneron Genetics Center discovered the GPR75 gene to be a key factor in developing obesity, a disease that over 650 million people suffer from around the world. It is inspiring when you consider that the comorbidities associated with obesity can manifest as a significant cost to insurance companies, making the drug more marketable. Over the past couple of years, the growth of the generics industry has been staggering, and Regeneron is fast becoming a major player. On August 5, the company announced its results for the second quarter of the year by beating the forecast results and publishing a better revenue and EPS. Fundamentally the company looks ready for a new all-time high, but dividends and share purchases are the areas where the company becomes a bit complicated. It is focused on its funds on R&D and has done exceptionally well, but it does not currently pay a dividend, and the net buyback rate is low. It is interesting how the investors will react at these price levels because it looks like that the price revert and confirm the $620 price level as a strong resistance. But if this correction in the long uptrend is temporary, the price easily reaches the previous all-time high at $666 and try to break through it. But it is also possible to picture the graph we saw between October and December last year in a downward direction to the price levels of $540 or far on South to $467. Looking at oscillator indicators, we can see that the correction starts from the RSI overbought zone. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carry a high-risk level. By registering and signing up, any client affirms their understanding of their accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals; therefore, it cannot be held liable nor guarantee any profits or losses.
NASDAQ:REGN
by legacyFXofficial
BioNTech $BNTX making a breakout from flag patternNASDAQ:BNTX is in a strong uptrend, and last week tested its 50 day MA and its bouncing really good. Today is in focus as the price broke out a continuation pattern with good volume. Also, the MACD is close to make a buy signal with a bullish crossover. BioNTech has a IBD relative strength rating of 97 and is Rank #2 in its industry, just behind NASDAQ:REGN which doesn't have good technicals. With this buy signal I have a target sell on $266.50 with a 2:1 risk/reward ratio.
NASDAQ:BNTXLong
by dpuleo19
ridethepig | Regeneron Pharmaceuticals📌 REGN pipeline (with particular focus on the early stages) CEMIPLIMAB, REGN3767, REGN1979, REGN4018, REGN5458, REGN5459, REGN5678, REGN5093, REGN5713-5714-5715 and REGN-COV2 all have a lot of potential with particular focus around oncology. As can be see with GILD, the covid positioning has already moved on a lot: we are ready to play chapter II and REGN is a name worth considering for those looking to add single stock opps to their portfolio. Buyers are clearly exercising control here on the Monthly chart at $600. To the topside there is very little in-between here and $1,000 as the next big level. Thanks as usual for keeping the feedback coming 👍 or 👎
NASDAQ:REGNLong
by ridethepig
Example of a failed Model reversal signal It was a big biotech week with many signals including CGEN, SEGN, BMRN but this one failed to hold. No Model is perfect and anyone who isn't trading with a rules based model will always underperform in the long run. No strong emotions for winners so the same must be applied to losers. We will certainly get another shot at this. Ingenuity Trading Model is an algorithm used in- Stock, Forex, Futures, and Crypto markets. The model is a Geometric Markov Model : Focuses on reversal and continuation wave structures In probability theory, a Markov model is a stochastic model used to predict randomly changing systems. Markov Models are used in all aspects of life from Google search to daily weather forecast. The randomly changing systems we focus on are the equity, futures, and forex markets. The geometric element of the model is the fractal sine wave structure you can find on any chart you look at across any market and across all time dimensions. Our model focuses on the current sine wave formation (current state)- geometric price formation along with its volume and volatility over a given time period and using that information to predict the future state- future price movement. For questions or more information feel free to contact me in the comment section or via private chat
NASDAQ:REGN
by IngenuityTrading
Regeneron's Covid Treatment First Drug Authorized By FDAMy last chart: November 22, 2020: Regeneron's Coronavirus Treatment Becomes First Antibody Cocktail to Earn Emergency Use Authorization from FDA (The Motley Fool). Regeneron Covid Drug Gets Emergency OK. Antibody drug cocktail casirivimab and imdevimab are allowed for use by people over age 12 with mild or moderate Covid-19. (the street). If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:REGNLong
by TopgOptions